Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 17, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details a specific transaction on January 16, 2007, where Abacus Corporate Trustees Limited, acting as trustee for the GlaxoSmithKline (US) Trust, transferred 75,300 Ordinary Share ADRs to participants in the GlaxoSmithKline Share Value Plan. The GSK US Trust is a grantor trust for employees or former employees of SmithKline Beecham Corporation and its subsidiaries.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that two directors, Dr. J-P Garnier and Dr. M M Slaoui, hold interests in the shares held in the GSK US Trust in the same capacity as other employees or former employees of SmithKline Beecham Corporation. The transaction was notified in accordance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Transaction Date: January 16, 2007.
- Shares Transferred: 75,300 Ordinary Share ADRs.
- Trustee: Abacus Corporate Trustees Limited (GSK US Trust).
- Beneficiaries: Participants in the GlaxoSmithKline Share Value Plan.
- Directors with Interest: Dr. J-P Garnier and Dr. M M Slaoui.
- Reporting Period: Ending January 17, 2007.